Table 3.
Results
| Site | SM CL | SM CL (non-sparing) | PG IL | PG IL (non-sparing) | PG CL | PG CL (non-sparing) | Sp C | Sp C (non-sparing) | V B ≥95% | V E ≥95% | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | mean | 33.7 | 51.5 | 34.2 | 33.3 | 21.8 | 21.4 | 42.1 | 41.9 | 99.3 | 98.9 |
| range | (46.5-57.3) | (24.7-41.6) | (16.6-54.3) | (16.3-53.2) | (12.2-31.8) | 14.2-32.1) | (37-50) | (35.8-49) | (98.9-99.9) | (98.2-99.5) | |
| B | mean | 32.4 | 49 | 27.9 | 27.8 | 22 | 21.9 | 36.4 | 36.3 | 99.7 | 98.5 |
| range | (44.3-52.8) | (29.7-39.5) | (16.4-55.5) | (16-55.7) | (16.7-30.6) | (16.7-30.3) | (23-49.8) | (23-49.8) | (99-99.9) | (97.9-98.9) | |
| C | mean | 35.1 | 47.1 | 28.7 | 29.1 | 21.9 | 22 | 40 | 39.8 | 98.5* | 98.9 |
| range | (43.7-52.4) | (26.6-40.6) | (16.5-48.2) | (17-46.3) | (13.6-30.9) | (14.5-30.7) | (30-44.9) | (29.7-45.3) | (96.2-99.6) | (97.9-98.9) | |
| D | mean | 33.4 | 46.4 | 21.2 | 21 | 16.2 | 16 | 36.4 | 36 | 99.6 | 98.3 |
| range | (42.2-51.8) | (30-36.8) | (12.7-35.7) | (12.4-35.6) | (10.7-26.1) | (10.3-26.3) | (24.7-41) | (24.4-41.2) | (99.1-99.9) | (97.6-98.9) |
A: oropharynx, elective dose 57.75 Gy (14 patients) Doses in Gy
B: larynx/hypopharynx, elective dose 57.75 Gy (7 patients) Sp C: spinal cord
C: oropharynx, elective dose 54.25 Gy (6 patients)
D: larynx/hypopharynx, elective dose 54.25 Gy (4 patients)
V B ≥95%:% of PTV boost receiving ≥95% of the prescribed dose
V E ≥95%:% of PTV elective receiving ≥95% of the prescribed dose
*: in 1 patient with T1 carcinoma of the soft palate, 96.2% of PTVboost received 95% of prescribed dose, this was accepted because of the fact that a large part of the PTVboost consisted of air.